Member Info for Misterh

Your account should be credited with what are usually referred to as subscription shares on the basis of 1 for every 17 that you held at close of business on Friday. Unlike with a rights issue these should show as having no value and can not be traded. Your account should also be credited with a much larger number of excess allocation shares should you wish to take advantage of those not participating in the open offer [if the share price stays where it is currently these will of course be massively scaled back]. Simply go to the corporate actions area and fill in the quantities of both that you wish to apply for.

I got almost exactly 50% of what I applied for and am also an existing shareholder. I suspect that you may have applied for a greater number of shares than me. In other words there may have been a basic allocation and then a percentage of the excess number applied for.

You will own the same number of shares but as they issued another 106.5M shares at the HK listing [the majority at an eye watering HK$0.98 to new investors], your percentage ownership of the company will have been diluted proportionately.

Has finally sparked some interest. Even got a small mention in yesterday's Mail On Sunday.
Looking forward to the updates on the Nordic and Aussie businesses mooted in the RNS of 1.10.
Bolt-on investments or even a divestment possible. The main focus is building value and I have increasing confidence in the company.

Goldman Sachs 12 month price target hit this morning with Afterpay closing at 94.46AUD. Is the APT SP starting to look a bit frothy? Even if it is, the same does not apply to TSL!

Another attempt to draw out weak holders this morning? If so, does not appear to be working. Need to watch MM's like a hawk on this stock.

The interim results out this morning make for great reading. To be honest, I was expecting a Covid19 related correction in the valuation of the portfolio from Jan-July 2020. Instead of this, the book value of the company has actually increased and just shy of 400p per share. The LEBC hiccup, that caused a completely unwarranted and disproportionate drop in the SP in 2019 is now ancient history. It's a shame that the Company is unable to start the share buy backs again due to the City Code on Takeovers. Perhaps they should consider a small tender offer instead.
All in all, a little gem of a company tucked away nicely in my SIPP for the future. Couldn't resist a small top up this morning.

Skid35:
In conclusion I meant to say that it is not science fiction that you could blow into a bag and get an instant diagnosis.
You just need a very sophisticated bag!

Continued.
We know that scientists around the globe are in a race to develop alternative methods of diagnosis and I know that a paper was recently published concerning the identification of SARS-COV-2 proteins from gargle samples from Covid19 patients using spectrometry.
I imagine that Kromek are somehow using their CZT technology for this purpose. My background is in animal disease, so although I am very familiar with Corona viruses, I'm afraid the physics is beyond me.
I see no reason however why this should not be possible and Dr Basu seems very confident of success. As he says, it will indeed be a unique and disruptive new technology.
The fact that the project started in 2018 gives them a flying start and there are high barriers to entry.
Should it pass trials early next year it should make major headlines in my opinion.
As shareholders, I think we are in for an exciting ride and although there will be inevitably be bumps in the road, I think it's well worth the risk.
I would be interested to hear any thoughts from others [especially physicists] on this thread.

Skid35, this is perhaps the most important question and I have been giving it some thought.
It must involve at least two separate technologies. Firstly a highly sophisticated filtration technique which separates out the various particles of interest [allergens and pathogens] according to size and eliminates the organic and inorganic debris of no interest. We are principally interested in the following: airborne bacteria [eg Legionella], bacterial spores [eg Anthrax], fungal spores [eg Cryptococcus] and of course viruses including Covid19. It would be valuable to identify all of these nasty pathogens, but let's just concentrate on the viruses, the smallest particles passing through the finest filter.
How then do we identify them?
The 'old school' method is by using PCR [Polymerase Chain Reaction] technology, which essentially amplifies small segments of nucleic acid in order to make a big enough sample for the viral genome to be identified. This is the technology used for example by Novacyte with their antigen detecting kits. It is essentially a laboratory technique.
We know that Kromek have said they are not using a 'laboratory technique' and that monitoring is continuous, which leads me to conclude that they are using a spectroscopic method which can identify specific molecules by their charge and mass.
They are therefore targeting proteins on the outside of the virus.

At least someone is happy to hoover up plenty of shares at this price. Let's just hope they have very deep pockets!

Just received this week's edition. Simon Thompson's copy on Kromek did not make the publication deadline but is sure to make an impact next week when published under the heading 'Tech winner in fight against Covid-19.' Should give a welcome and timely boost when reaches IC's 35,000 or so readers, many of whom don't have digital access.

Yes, a really strange day. I'm no chartist but just take a gander at the one day candlestick chart. We have a textbook hammer on astronomical volume [56M shares or more than 16% of company traded]. Hopefully a clear out of bears and stale bulls taking place. Let's hope it heralds a reversal of the downward trend!

Extremely positive update. Perhaps most significant comment is 'the company should have the funding in place to operate without the need to tap shareholders.' That was my main concern.

Mustn't lose sight of the potential in the biological threat detection technology:
'Once fully developed over the next few months, the technology should be able to sample air and identify the presence of any biological pathogen - including COVID-19 or any mutant version that may emerge over time.'
Just imagine the reaction to positive news flow here. As we all know, buying at the point of maximum pessimism often pays handsomely [just don't bet your shirt on it]

https://www.fool.com.au/2020/10/06/why-the-afterpay-asxapt-share-price-is-charging-higher-today/

With the SP of Afterpay moving up to AUD 83.48 following a positive broker note from Goldman Sachs, the new spot sum of the parts valuation [using figures from IC article 17.9] moves to 82p per share.

I think it will take more than a tip to get this moving again. It usually pays to be extremely cautious when management go into an extended period of radio silence, although no news does not always augur bad news. This will simply drift lower and lower until the BOD deign to communicate with their shareholders. I think we deserve nothing less.

TSL mentioned in today's IC article. One strand to the investment case is that the colossus Tencent could ultimately have Afterpay in its cross hairs having already acquired a 5% holding. Any further stake building could put a rocket under the SP.

I note that they acquired the above for a bargain price of £1.8M from the liquidator of Redhall Group in June 2019. I don't know how much they've invested in it to date, but I think we can assume it's worth a significant multiple of this now. With total contract wins of at least £48M under their belt to date, AVG have again shown their ability to turn around a business in short order. Good value on offer here for the patient investor.